The AIBL – Longitudinal Study of Ageing is designed to assess the biomarkers of Alzheimer’s Disease (AD) by studying Australian participants blood based, imaging, and lifestyle biomarkers over time.
There is no known cure for Alzheimer’s Disease. The challenge was to define a set of biomarkers that are associated with the early identification of AD.
By identifying biomarkers for the early identification of AD, we can help in the selection of participants for clinical trials, reducing their cost, and increasing their benefit.
Our team assessed fluid based biomarkers that are associated with disease pathology as measured via PET imaging.
Using data from the Australian Imaging, Biomarkers and Lifestyle study of ageing, we defined the disease trajectory for AD, predicting that the onset of pathology burden begins up to 20 years prior to the onset of clinical symptoms. Further to this, along with our collaborators in Melbourne and Japan, we identified a biomarker that has greater than 90% accuracy to detect AD pathology in any person over the age of 60. This was a world first, and was published in the journal Nature.